#USA #Glioblastoma #Sapience Therapeutics #Tarrytown #Lucicebtide

Sapience Therapeutics to Present at ASCO 2025

Sapience Therapeutics, a clinical-stage biotechnology company based in Tarrytown, New York, has announced an oral presentation featuring the promising Phase 2 clinical trial results for its innovative peptide therapeutic, lucicebtide, at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. This significant event is set to take place from May 30 to June 3, 2025, in Chicago and online, attracting worldwide attention in the field of oncology.

Presentation Details

The presentation will delve into the use of lucicebtide, previously known as ST101, in patients dealing with glioblastoma, an aggressive form of brain cancer. The study focuses on how the therapy antagonizes the protein C/EBPβ to target mesenchymal cell transition and inhibit the polarization of immunosuppressive M2 macrophages, which are known to complicate treatment outcomes in glioblastoma patients.

Key Presentation Information:

• - Title: Use of lucicebtide (ST101) in glioblastoma patients by antagonism of C/EBPβ-dependent mesenchymal cell transition and immunosuppressive M2 macrophage polarization
• - Abstract Number: 2016
• - Session Type: Rapid Oral Abstract – Central Nervous System Tumors
• - Date and Time: Saturday, May 31, 2025, at 3:00 PM - 4:30 PM CDT
• - Presenting Author: Dr. Fabio M. Iwamoto, MD, from the Division of Neuro-Oncology at New York-Presbyterian/Columbia University Irving Medical Center.

Participants of the meeting will gain insights into the data gathered from the Phase 2 trial, which is vital for understanding the efficacy of lucicebtide, a first-in-class antagonist aiming to improve the treatment landscape for glioblastoma patients.

About Lucicebtide

Lucicebtide is a cutting-edge therapy that has recently completed its main dose expansion study in recurrent glioblastoma (rGBM), as outlined in clinical trial registry NCT04478279. Current investigations include a sub-study of lucicebtide in conjunction with radiation therapy and temozolomide for patients newly diagnosed with glioblastoma, alongside evaluations for its solo use in those with recurrent forms of the disease. The FDA has recognized lucicebtide with Fast Track designation for rGBM, alongside orphan drug status for glioma from the U.S. FDA and the European Commission.

About Sapience Therapeutics

Sapience Therapeutics is committed to forging advancements in cancer treatment through the discovery of peptide-based therapeutics that address both oncogenic and immune dysregulations driving cancer progression. With an array of in-house capabilities, Sapience has cultivated a robust pipeline branded SPEARs™ (Stabilized Peptides Engineered Against Regulation), designed to target traditionally tough cancer pathways. Additionally, their unique molecules known as SPARCs™ (Stabilized Peptides Against Receptors on Cancer) allow for targeted delivery of radioisotopes to cancer cells, bolstering the effectiveness of current treatments.

Sapience is strategically advancing its lead candidates, including lucicebtide and ST316—a first-in-class antagonist of β-catenin—through pivotal Phase 2 clinical trials. As cancer treatment paradigms shift, the outcomes of these trials may reshape approaches to managing glioblastoma and similar malignancies.

For further details, you can visit Sapience Therapeutics’ official website and connect with them on LinkedIn for latest updates and information pertaining to ongoing research and clinical advancements.

This presentation at ASCO 2025 marks a pivotal point in their mission to deliver innovative treatments to patients facing challenging cancers like glioblastoma, potentially paving the way for improved outcomes and quality of life.

Conclusion

Indeed, as the ASCO 2025 Annual Meeting approaches, the spotlight will be on Sapience Therapeutics and its groundbreaking work. Stay tuned for what promises to be a revealing look into the future of glioblastoma therapies.